Literature DB >> 2107050

Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies.

E Rondeau1, B Mougenot, R Lacave, M N Peraldi, E K Kruithof, J D Sraer.   

Abstract

The persistency of fibrin deposits in the kidney during renal diseases could reflect either a defective release of plasminogen activators (PA) or a local excess of PAI. In order to investigate this question, we studied human renal biopsies by immunofluorescence technique with specific antibodies for fibrin, tissue-type plasminogen activator (t-PA), urokinase (u-PA), PAI-1 and PAI-2. By this technique t-PA could be detected in the glomerular flocculus and the endothelium of small arteries of the normal control kidneys. We failed to detect significant fluorescence with other antibodies in normal kidneys. Conversely, in cases of vascular nephropathy with thrombosis the positive fluorescence obtained with anti-fibrin antibodies at the site of thrombosis was associated with a positive fluorescence with anti-PAI-1 and to a lesser extent with anti-t-PA antibodies. u-PA and PAI-2 were not detected in these lesions. Similarly in the most severe forms of crescentic glomerulonephritis, extracapillary fibrin deposits were associated with PAI-1. In one case u-PA was also detected. This is in agreement with our previous findings that glomerular epithelial cells release both PAI-1 and the inactive form of u-PA (pro u-PA). Thus, our results support the hypothesis that PAI-1, which is able to inhibit both t-PA and u-PA, may play a major role in the persistency of fibrin deposits in the human kidneys during pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107050

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  13 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  New era for drug discovery and development in renal disease.

Authors:  Toshio Miyata; Katsushi Kikuchi; Hideyasu Kiyomoto; Charles van Ypersele de Strihou
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

3.  A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.

Authors:  Jiandong Zhang; Chunyan Gu; Daniel A Lawrence; Alfred K Cheung; Yufeng Huang
Journal:  Exp Physiol       Date:  2014-01-17       Impact factor: 2.969

4.  Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.

Authors:  J Hagège; M N Peraldi; E Rondeau; C Adida; F Delarue; R Medcalf; W D Schleuning; J D Sraer
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

5.  Renal Vein Thrombosis and Selective Arterial or Venous Thrombolytic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

6.  Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Authors:  Friedrich Modde; Putri Andina Agustian; Juliane Wittig; Maximilian Ernst Dämmrich; Vinzent Forstmeier; Udo Vester; Thurid Ahlenstiel; Kerstin Froede; Ulrich Budde; Anne-Margret Wingen; Anke Schwarz; Svjetlana Lovric; Jan Thomas Kielstein; Carsten Bergmann; Nadine Bachmann; Mato Nagel; Hans Heinrich Kreipe; Verena Bröcker; Clemens Luitpold Bockmeyer; Jan Ulrich Becker
Journal:  Virchows Arch       Date:  2013-03-09       Impact factor: 4.064

Review 7.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

8.  The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation.

Authors:  Samuel N Heyman; Zohair Hanna; Taher Nassar; Ahuva Shina; Sa'ed Akkawi; Marina Goldfarb; Seymour Rosen; Abd-Al Roof Higazi
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

9.  Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease.

Authors:  M Lassila; K Fukami; K Jandeleit-Dahm; T Semple; P Carmeliet; M E Cooper; A R Kitching
Journal:  Diabetologia       Date:  2007-04-06       Impact factor: 10.122

10.  Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA.

Authors:  P G Tipping; J H Erlich; J Apostolopoulos; N Mackman; D Loskutoff; S R Holdsworth
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.